Cancer Research Technology, the quasi-corporate venturing unit of charity Cancer Research UK, and venture capital firm Kurma Life Sciences Partners have spun out Blink Therapeutics.
Blink’s technology is based on research carried out by the founding scientists Facundo Batista, at Cancer Research UK’s London Research Institute in collaboration with Vincenzo Cerundolo at the University of Oxford.
Kurma has committed up to £1.1m ($1.8m) as seed financing and up to £6.6m in further financing for Blink.
Richard Treisman, director of Cancer Research UK’s London Research Institute, said: "We host 46 research groups carrying out life-saving research to understand the fundamental biology of cancer – an essential step in the development of new approaches to diagnose and treat the disease."